Table 1

Descriptive characteristics of 134 female breast cancer survivors in HEAL Study
Not obese (n = 39) Obesea(n = 95) p-value
Characteristics at 24 month post-diagnosis assessment
CRP (mg/L),Mean (SD) 1.2 (1.5) 3.4 (3.7) <.0001
SAA (mg/L),Mean (SD) 4.2 (2.2) 9.3 (17.9) 0.008
Age at assessment,Mean (SD) 53.2 (8.8) 61.4 (10.3) <.0001
Postmenopausalb- yes,n (%) 18 (52.6) 81 (91.0) <.0001
Weight (kg)c,Mean (SD) 58.9 (7.2) 74.3 (12.1) <.0001
BMI (kg/m2),Mean (SD) 21.9 (2.5) 28.4 (4.3) <.0001
Percentage of body fat,Mean (SD) 29.7 (5.0) 42.6 (4.7) <.0001
Hip Circumference (cm),Mean (SD) 96.0 (5.5) 110 (9.3) <.0001
Waist (cm),Mean (SD) 74.2 (7.2) 92.4 (11.2) <.0001
Weight Change,n (%) 0.06
Loss 7 (18.0) 5 (5.3)
No Changed 22 (56.4) 66 (69.5)
Gain 10 (25.6) 24 (25.3)
Physical Activity (MET hrs/week),n (%) 44.7 (45.4) 28.2 (24.9) 0.04
Change in Physical Activity since baselinee(MET-hrs/week) 6.7 (29.5) -5.3 (31.6) 0.04
History of Arthritis – yes, n (%) 5 (12.8) 50 (52.6) <.0001
Hypertensionf 6 (15.4) 31 (33.0) 0.04
Past and current medication use - yes,n (%)
Tamoxifeng 14 (35.9) 41 (43.2) 0.44
NSAID 8 (20.5) 40 (42.1) 0.02
Chemotherapyh 9 (23.1) 19 (20.0) 0.69

a Obese ≥35% Body Fat, not obese < 35% Body Fat.

b I non obese and 6 obese excluded due to unknown menopausal status.

c Weight at follow-up is taken at the second DEXA measurement.

d Weight change within 5% change in body weight since baseline.

e Baseline is approximately 6 months post-diagnosis. Follow-up is approximately 30 months post-diagnosis.

f 1 obese participant answered "Don't know" and was excluded.

g Current use of tamoxifen or over the counter or prescription non-steroidal anti-inflammatory drug (NSAID).

h 2 non-obese participants refused to answer and were excluded.

Dee et al.

Dee et al. BMC Cancer 2012 12:343   doi:10.1186/1471-2407-12-343

Open Data